A Phase II Trial of Weekly Intravenous Ranpirnase (Onconase), a Novel Ribonuclease in Patients with Metastatic Kidney Cancer

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2001 Sep 20

PMID 11561684

Citations 7

Authors

N J Vogelzang

M Aklilu

W M Stadler

M C Dumas

S M Mikulski

Affiliations

Soon will be listed here.

Abstract

Ranpirnase (Onconase) is the first ribonuclease to enter cancer clinical trials. In prior phase II trials, responses were seen in mesothelioma and other solid tumors. This phase II trial tested ranpirnase (480 microg/m2/w) in 14 patients with refractory advanced renal cell cancer. The median performance status was zero and the median age was 55. All patients had prior immunotherapy and three had prior chemotherapy. No responses were seen in 14 patients. The median survival from on study was 16 months (range two to 28 months). At this dose and schedule ranpirnase has minimal activity in metastatic renal cell cancer.

Citing Articles

Role of the Ribonuclease ONCONASE in miRNA Biogenesis and tRNA Processing: Focus on Cancer and Viral Infections.

Menegazzi M, Gotte G Int J Mol Sci. 2022; 23(12).

PMID: 35742999 PMC: 9223570. DOI: 10.3390/ijms23126556.

Strengths and Challenges of Secretory Ribonucleases as AntiTumor Agents.

Castro J, Ribo M, Vilanova M, Benito A Pharmaceutics. 2021; 13(1).

PMID: 33435285 PMC: 7828032. DOI: 10.3390/pharmaceutics13010082.

Targeted delivery of immuno-RNase may improve cancer therapy.

Sun M, Sun L, Sun D, Zhang C, Li M Cancer Cell Int. 2018; 18:58.

PMID: 29686536 PMC: 5902972. DOI: 10.1186/s12935-018-0546-7.

Binase Immobilized on Halloysite Nanotubes Exerts Enhanced Cytotoxicity toward Human Colon Adenocarcinoma Cells.

Khodzhaeva V, Makeeva A, Ulyanova V, Zelenikhin P, Evtugyn V, Hardt M Front Pharmacol. 2017; 8:631.

PMID: 28955235 PMC: 5600959. DOI: 10.3389/fphar.2017.00631.

Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent.

Altomare D, Rybak S, Pei J, Maizel J, Cheung M, Testa J BMC Cancer. 2010; 10:34.

PMID: 20137089 PMC: 2829496. DOI: 10.1186/1471-2407-10-34.

References

Ryan C, Vogelzang N, Dumas M, Kuzel T, Stadler W . Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials. Cancer. 2000; 88(6):1317-24. View

Atzpodien J, Hanninen E, Kirchner H, Bodenstein H, Pfreundschuh M, Rebmann U . Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol. 1995; 13(2):497-501. DOI: 10.1200/JCO.1995.13.2.497. View

Vogelzang N, Stadler W . Kidney cancer. Lancet. 1998; 352(9141):1691-6. DOI: 10.1016/S0140-6736(98)01041-1. View

Rini B, Vogelzang N, Dumas M, Wade 3rd J, Taber D, Stadler W . Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000; 18(12):2419-26. DOI: 10.1200/JCO.2000.18.12.2419. View

Mosimann S, Johns K, Ardelt W, Mikulski S, Shogen K, James M . Comparative molecular modeling and crystallization of P-30 protein: a novel antitumor protein of Rana pipiens oocytes and early embryos. Proteins. 1992; 14(3):392-400. DOI: 10.1002/prot.340140308. View

Dutcher J, Atkins M, Fisher R, Weiss G, Margolin K, Aronson F . Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. Cancer J Sci Am. 1998; 3 Suppl 1:S73-8. View

Stadler W, Kuzel T, Dumas M, Vogelzang N . Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol. 1998; 16(5):1820-5. DOI: 10.1200/JCO.1998.16.5.1820. View

Rini B, Selk L, Vogelzang N . Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res. 1999; 5(10):2766-72. View

Tippin D, Reeves W, Vogelzang N . Diagnosis and treatment of leptomeningeal metastases in a patient with renal carcinoma responding to 5-fluorouracil and gemcitabine. J Urol. 1999; 162(1):155-6. DOI: 10.1097/00005392-199907000-00038. View

10.

Motzer R, Schwartz L, Law T, Murphy B, Hoffman A, Albino A . Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol. 1995; 13(8):1950-7. DOI: 10.1200/JCO.1995.13.8.1950. View

11.

Stadler W, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang N . Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol. 1999; 17(8):2541-5. DOI: 10.1200/JCO.1999.17.8.2541. View

12.

Vogelzang N, Mani S, Schilsky R, Ansari R, Taber D, Rhinehart S . Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res. 1998; 4(4):929-34. View

13.

Motzer R, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J . Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17(8):2530-40. DOI: 10.1200/JCO.1999.17.8.2530. View

14.

Mikulski S, Ardelt W, Shogen K, BERNSTEIN E, Menduke H . Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos. J Natl Cancer Inst. 1990; 82(2):151-3. DOI: 10.1093/jnci/82.2.151-a. View

15.

Mikulski S, Chun H, Mittelman A, Panella T, Puccio C, Shogen K . Relationship between response rate and median survival in patients with advanced nonsmall cell lung-cancer - comparison of onconase(r) with other anticancer agents. Int J Oncol. 2011; 6(4):889-97. DOI: 10.3892/ijo.6.4.889. View

16.

Mosimann S, Ardelt W, James M . Refined 1.7 A X-ray crystallographic structure of P-30 protein, an amphibian ribonuclease with anti-tumor activity. J Mol Biol. 1994; 236(4):1141-53. DOI: 10.1016/0022-2836(94)90017-5. View

17.

Atkins M, Sparano J, Fisher R, Weiss G, Margolin K, Fink K . Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol. 1993; 11(4):661-70. DOI: 10.1200/JCO.1993.11.4.661. View

18.

Iordanov M, Ryabinina O, Wong J, Dinh T, Newton D, Rybak S . Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res. 2000; 60(7):1983-94. View

19.

Bukowski R . Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer. 1997; 80(7):1198-220. DOI: 10.1002/(sici)1097-0142(19971001)80:7<1198::aid-cncr3>3.0.co;2-h. View

20.

. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet. 1999; 353(9146):14-7. View